Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.42 |
| ▸ | KDR | P35968 | 8/20 | 0.42 |
| ▸ | KIF5B | P33176 | 8/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20143871 | 0.87 | PDPK1 (0.46) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL31554502 | 0.83 | RET (0.45) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL29612554 | 0.80 | SRC (0.55) | EGFRSRCERBB2 | |
| SCHEMBL5465258 | 0.80 | SRC (0.39) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL1898838 | 0.80 | SRC (0.55) | EGFRSRCERBB2 | |
| SCHEMBL5929884 | 0.79 | CSF1R (0.56) | CSF1R | |
| SCHEMBL24117644 | 0.77 | ENPP1 (0.49) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL4741688 | 0.75 | MAP2K1 (0.54) | EGFRSRCERBB2 | |
| SCHEMBL296984 | 0.74 | ENPP1 (0.63) | RETKDRKIF5BEGFR | |
| SCHEMBL30054610 | 0.74 | ENPP1 (0.63) | RETKDRKIF5BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | RET 2476/4885KDR 4095/4885KIF5B 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.